HIV may be becoming less fit as it adapts to the immune system
Number of people infected with drug-resistant HIV in Europe has risen by around 35%
Big differences in virological outcomes among people taking first-line HIV therapy in resource-limited settings
Persisently detectable viral load at any level increases risk of HIV treatment failure
New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy
Can people with resistant HIV omit NRTIs when switching from a failing regimen?
